Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Heart failure is a syndrome of huge and growing importance worldwide. It is widely accepted that the energy status of the myocardium in heart failure is impaired, irrespective of etiology. Agents which modify cardiac substrate utilisation have the potential to ameliorate this energy deficiency by increasing cardiac mechanical efficiency. This may represent a new therapeutic paradigm in heart failure. In this review we discuss existing and new agents that alter cardiac substrate use and summarise the data on clinical efficacy.

Original publication

DOI

10.1016/j.pharmthera.2008.05.007

Type

Journal article

Journal

Pharmacol Ther

Publication Date

09/2008

Volume

119

Pages

264 - 274

Keywords

Animals, Carbohydrate Metabolism, Energy Metabolism, Heart Failure, Humans, Models, Biological, Myocardium, Oxidation-Reduction